Medical Condition

pancreatic cancer

Total Trials

46

Recruiting Now

46

Trial Phases

Phase 1, EARLY_Phase 1, Phase 4

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a 5-year survival rate under 13% due to late-stage diagnosis and poor response to conventional chemotherapy. Clinical trials are urgently needed: fewer than 10% of patients are eligible for curative-intent surgery at diagnosis, and systemic therapy extends median survival in metastatic disease by only months. This landscape makes PDAC one of the most active and highest-priority areas in oncology research.

Active trials investigate KRAS inhibitors (adagrasib, sotorasib in KRAS-mutant disease β€” nearly universal in PDAC), antibody-drug conjugates (zolbetuximab for CLDN18.2-positive tumors), cancer vaccines including mRNA neoantigen approaches (Moderna/Merck mRNA-4157), CAR-T cell therapies, and PARP inhibitors for the ~5β€“7% with germline BRCA mutations. Combination approaches with targeted stromal modulators aim to overcome the desmoplastic tumor microenvironment.

Germline testing for BRCA1/2, PALB2, and ATM is recommended for all PDAC patients, as mutations alter both prognosis and eligibility for PARP inhibitor trials.

Frequently Asked Questions — pancreatic cancer Clinical Trials

How many clinical trials are currently recruiting for pancreatic cancer?

ClinicalMetric currently tracks 46 actively recruiting clinical trials for pancreatic cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 46. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for pancreatic cancer?

pancreatic cancer research spans Phase 1 (11 trials), Phase 2 (10 trials), Phase 3 (1 trial), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a pancreatic cancer clinical trial?

Eligibility criteria for pancreatic cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Phase 4

Top Sponsors

Changhai Hospital 3 trials

University of Missouri-Columbia 2 trials

H. Lee Moffitt Cancer Center and Research Institute 2 trials

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 2 trials

ArriVent BioPharma, Inc. 1 trial

pancreatic cancer

Frequently Asked Questions — pancreatic cancer Clinical Trials

Recruiting Clinical Trials

Related Conditions